Patents Examined by Michael Schmitt
  • Patent number: 9914718
    Abstract: An anhydrous crystalline form of S-equol has been discovered. Form I, the anhydrous crystalline form of S-equol has been isolated and characterized for the first time. As compared to other forms of S-equol, such as the known hydrate or other solvate forms, the anhydrous crystalline form of S-equol has improved properties.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 13, 2018
    Inventor: Richard L. Jackson
  • Patent number: 9890144
    Abstract: Compounds and embodiments of a method for treating and/or preventing autoimmune diseases are disclosed. The method includes administering to a subject having an autoimmune disease, such as an inflammatory bowel disease, a therapeutically effective amount of a compound according to formula I wherein X and Y independently are O or NR1; each R1 is independently H or C1-C6 alkyl; ring A is aryl; each R2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two R2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; R3 and R4 independently are H or C1-C6 alkyl; and R5 is halo, cyano, or C1-C6 alkyl.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: February 13, 2018
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
  • Patent number: 9884856
    Abstract: The present invention involves novel crystal forms of Dabrafenib mesylate and preparation method thereof, wherein the novel crystal forms are more stable in water or an aqueous system, and have greater solubility and dissolution rate in water, thus having better stability and bioavailability compared with the existing crystal forms.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: February 6, 2018
    Inventors: Haiping Lao, Xiaoxia Sheng, Xiaohong Sheng
  • Patent number: 9884802
    Abstract: The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, OH or F; R2 is H, OH, F or CH2—OH; R3 is H, OH, F or CH2Ph; R4 is H, OH or F; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 6, 2018
    Inventors: Lyne Gagnon, Pierre Laurin, Brigitte Grouix, Lilianne Geerts, François Sarra-Bournet, Martin Leduc, Shaun Abbott, Boulos Zacharie, Jean-François Bienvenu, Valérie Perron
  • Patent number: 9867832
    Abstract: The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: January 16, 2018
    Assignee: LG CHEM, LTD.
    Inventors: Seok Goo Cho, Na Youn Kim, Eun Jung Kim, Keon Il Im, Jung Yeon Lim, Eun Joo Jeon
  • Patent number: 9861605
    Abstract: A composition including a triglyceride containing glycerol which is esterified with three fatty acids, wherein the three fatty acids include at least one fatty acid selected from caprylic acid, capric acid, ?-linolenic acid, linoleic acid, oleic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid. The total amount of caprylic acid, capric acid, a-linolenic acid, linoleic acid, oleic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid is greater than 60%, based on the total weight of the fatty acids in a base or starting emulsion. The various physical mixtures of triglycerides containing the primary therapeutic fatty acid can be blended to form pre-defined amounts for the treatment of various acute pathological conditions.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: January 9, 2018
    Inventor: David F. Driscoll
  • Patent number: 9850214
    Abstract: Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: December 26, 2017
    Inventors: Ashley Sue McCarron, Todd B. Sells, Matthew Stirling, Stephen G. Stroud
  • Patent number: 9849104
    Abstract: Methods and formulations to reduce elevated levels of lipids and apolipoprotein B in subjects having type IIb hyperlipidemia. Methods for preventing, delaying or regressing complications of lipid disorders, including; type IIb hyperlipidemia, NAFLD, and NASH. Methods for preventing or delaying primary and secondary cardiovascular events. Kits useful for such methods. Methods for reducing hepatic fibrosis. Methods for reducing plasma fibrinogen levels.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: December 26, 2017
    Assignee: Gemphire Therapeutics Inc.
    Inventors: Charles L. Bisgaier, Daniela Carmen Oniciu
  • Patent number: 9849135
    Abstract: Disclosed herein are methods of treating or preventing a viral infection resulting from infection by a flavivirus, comprising administering to a subject a small molecule inhibitor of USP14, represented by Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, chemically-protected form, enantiomer or stereoisomer thereof, and pharmaceutical compositions comprising an effective amount of a compound of Formula (I) for use in the method.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: December 26, 2017
    Assignees: President and Fellows of Harvard College, Health Research, Inc.
    Inventors: Daniel J. Finley, Dilip Nag, Laura D. Kramer
  • Patent number: 9850228
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: December 26, 2017
    Inventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Patent number: 9850264
    Abstract: The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: December 26, 2017
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, John E. Donello, Veena Viswanath
  • Patent number: 9840528
    Abstract: Platinum(II) complexes having thione-based heterocyclic ligands as anticancer agents. The central platinum atom is coordinated by four of the ligands, each having a five-, six- or seven-membered heterocyclic ring with two nitrogen atoms at positions 1 and 3 of the ring and a thiocarbonyl group at position 2. Pharmaceutical compositions incorporated the platinum(II) complexes, methods of synthesizing the complexes and methods of treating cancers with the complexes or pharmaceutical compositions thereof are also described.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: December 12, 2017
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Muhammad Altaf, Anvarhusein Abdulkadir Isab
  • Patent number: 9828384
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: November 28, 2017
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Patent number: 9814776
    Abstract: The pharmaceutical formulations according to the present invention include an alkyl sulfate salt and a compound represented by general formula (I) below (where R1 to R4 are as defined in the specification) or tautomers thereof, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: November 14, 2017
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jun Nihira, Kensuke Okazaki, Shiho Yoshimura
  • Patent number: 9801873
    Abstract: Among other things, a method of treating a human having brain cancer is, the method comprising administering via a non-continuous dosing regimen to the human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug or a pharmaceutically acceptable salt thereof, wherein the non-continuous dosing regimen comprises administering the pharmaceutical composition no more frequently than once every seven days for at least two dosings.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: October 31, 2017
    Assignee: Nektar Therapeutics
    Inventors: Michael A. Eldon, Shibani S. Harite, Tamra L. Barker
  • Patent number: 9801832
    Abstract: The present patent application relates to a pharmaceutical composition, characterized in that it comprises at least one active ingredient which can bring about a singlet oxygen-independent direct catalase inactivation and that the composition further comprises at least one active ingredient that leads to inactivation of catalase as a result of modulation of the nitrogen oxide or superoxide anion metabolism of the cells and subsequent singlet oxygen formation.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: October 31, 2017
    Assignee: Universitaetsklinikum Freiburg
    Inventor: Georg Bauer
  • Patent number: 9783534
    Abstract: The present invention relates to a novel crystalline form of 2-{3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenylmethansulphonate, to processes for its preparation and to its use in agrochemical preparations.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: October 10, 2017
    Inventors: Britta Olenik, Stefan Hillebrand, Pierre Wasnaire, Martin Weiss, Ulrike Wachendorff-Neumann
  • Patent number: 9758489
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: September 12, 2017
    Inventor: George D. Hartman
  • Patent number: 9750732
    Abstract: The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: September 5, 2017
    Inventors: Raphael Schiffmann, Fanny Mochel, Lawrence Sweetman, Sabrina Forni
  • Patent number: 9751870
    Abstract: The invention relates to the use of a compound of formula I wherein A1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen or cycloalkyl; A2 is phenyl; R2 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, S-lower alkyl substituted by halogen, S(O)2-lower alkyl substituted by halogen; n is 1 or 2; or a pharmaceutically acceptable acid addition salt, or a racemic mixture or its corresponding enantiomer and/or optical isomers thereof, for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: September 5, 2017
    Inventors: Caterina Bissantz, Christophe Grundschober, Matthias Nettekoven, Jean-Marc Plancher, Walter Vifian